Semaglutide News and Research

Latest Semaglutide News and Research

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Researchers examine the role of GLP-2 in regulating food intake through its effects on gastrointestinal motility and satiety signals, offering insights into potential obesity treatments.

12 Sep 2024

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

As more people with type 2 diabetes (T2D) are taking medications to help manage blood sugar levels and weight loss, concerns about whether these drugs are safe have emerged.

12 Sep 2024

Women experience greater weight loss with tirzepatide compared to men

All doses of tirzepatide, a medication approved in the EU to treat type 2 diabetes and obesity, consistently reduced body weight in women and men, but women experienced greater weight loss, according to new post hoc research to be presented at this year's Annual Meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

11 Sep 2024

Obesity medication liraglutide safe and effective in children under 12, research finds

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September), and published simultaneously in the New England Journal of Medicine (NEJM), has found.

10 Sep 2024

Once-a-day oral weight loss drug shows promising results in reducing body weight

Individuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, the annual meeting of the European Association for the Study of Diabetes (EASD) in Madrid, Spain (9-13 September) will hear.

10 Sep 2024

GLP-1 receptor agonists show promise in treating substance use disorders

A systematic review reveals that GLP-1 receptor agonists may help reduce certain substance use disorders, but findings are inconsistent due to study variability and patient differences.

9 Sep 2024

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

French researchers have developed a new drug delivery system that could cut the dosing schedule for the type 2 diabetes and weight control drug semaglutide to just once a month, according to new research to be presented at this year's annual meeting of The European Association for the Study of Diabetes (EASD), Madrid (9-13 Sept).

9 Sep 2024

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide significantly reduces all-cause mortality in non-diabetic obese patients, particularly by lowering infection-related deaths during the COVID-19 pandemic. However, the study's findings should be interpreted with caution due to potential competing risks and unique pandemic circumstances.

5 Sep 2024

Semaglutide does not increase risk of depression or suicidal thoughts

Taking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania published this week in JAMA Internal Medicine.

4 Sep 2024

Study reassures patients about semaglutide safety

4 Sep 2024

European Society of Cardiology highlights underrecognized link between obesity and heart disease

Obesity is a key factor in cardiovascular disease, prompting the ESC to recommend comprehensive strategies for prevention and management to reduce health risks.

3 Sep 2024

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

2 Sep 2024

Is semaglutide use during breastfeeding safe?

Researchers found no detectable levels of semaglutide in breast milk, suggesting minimal risk to breastfed infants, but highlighted the need for monitoring maternal nutrition and milk production.

2 Sep 2024

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Patients taking semaglutide injections are less likely to die of any cause, including from cardiovascular disease and infections like COVID-19, an international study led by researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, finds.

30 Aug 2024

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing serious COVID-19 related events and improving heart failure (HF) symptoms, according to six new substudies published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

Semaglutide, the popular anti-obesity drug, reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established cardiovascular disease without diabetes, according to a new study published in JACC, the flagship journal of the American College of Cardiology.

30 Aug 2024

ESC consensus statement highlights obesity's impact on cardiovascular disease

The ESC Clinical Consensus Statement on Obesity and Cardiovascular Disease, presented at this year's ESC Congress (London, UK, 30 August to 2 September) summarizes current evidence on the epidemiology and etiology of obesity; the interplay between obesity, cardiovascular risk factors and cardiac conditions; the clinical management of patients with cardiac disease and obesity; and weight loss strategies including lifestyle changes, interventional procedures, and anti-obesity medications with particular focus on their impact on cardiometabolic risk and cardiac outcomes.

30 Aug 2024

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

A study published in eClinicalMedicine found that tirzepatide outperforms semaglutide in reducing the risk of type 2 diabetes and major cardiovascular events among individuals with obesity, with or without existing diabetes, while also achieving greater weight loss.

28 Aug 2024

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Semaglutide shows promise in reducing cardiovascular risks in obese patients with heart failure, improving outcomes in a recent large-scale clinical trial.

27 Aug 2024

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

If Medicare Part D narrowly defines cardiovascular disease, the majority of patients would remain ineligible while new federal spending could still exceed $10 billion

27 Aug 2024

Semaglutide News and Research

Latest Semaglutide News and Research

GLP-2 regulates appetite by influencing gut-brain communication and gastrointestinal motility

Real-world evidence highlights safety profile of tirzepatide in managing type 2 diabetes

Women experience greater weight loss with tirzepatide compared to men

Obesity medication liraglutide safe and effective in children under 12, research finds

Once-a-day oral weight loss drug shows promising results in reducing body weight

GLP-1 receptor agonists show promise in treating substance use disorders

New hydrogel system could extend semaglutide dosing to once a month for type 2 diabetes patients

Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic

Semaglutide does not increase risk of depression or suicidal thoughts

Study reassures patients about semaglutide safety

European Society of Cardiology highlights underrecognized link between obesity and heart disease

Tirzepatide outperforms insulin in controlling diabetes and promoting weight loss in clinical trials

Is semaglutide use during breastfeeding safe?

Semaglutide cuts death rates from cardiovascular disease and COVID-19

Semaglutide's impact on cardiovascular health expands beyond weight loss

Semaglutide lowers COVID-19-related deaths in cardiovascular patients with obesity

ESC consensus statement highlights obesity's impact on cardiovascular disease

Tirzepatide beats semaglutide in lowering diabetes risk and cardiovascular events in obesity patients

Semaglutide shown to cut major adverse cardiovascular events in heart failure patients

Study warns of high Medicare costs for semaglutide even with restrictive CVD definition

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Semaglutide News and Research

Latest Semaglutide News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in